Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies
Sign Up to like & getrecommendations! Published in 2019 at "Xenobiotica"
DOI: 10.1080/00498254.2019.1581960
Abstract: Abstract 1. The absorption, metabolism, and excretion of a single oral 450-mg dose of [14C]-(S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, was investigated in humans. Mass balance was achieved with ∼94.6% of the administered dose… read more here.
Keywords: trifluoromethyl imidazol; imidazol propanamido; cyclopentyl; metabolism ... See more keywords